0 -0.000493470999088959 -0.000608108108108012 0.000607348921955758 -0.000227755845733382 0.00155633161251148 -0.00117673853628911 0.000455511691466765
Sign Up Today X
Thanks for submitting the form.
Stockreport

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis [Yahoo! Finance]

Illumina, Inc. (ILMN)  More Company Research Source: Yahoo! Finance
Last illumina, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: illumina.com/company/investor-information.html
VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis. Shares of the company were down 6.1% on Sept. 19 following the announcement of the news. Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach's ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years. Year to date, shares of Vanda have increased 10.2% compared with the industry's rise of 0.4%. Image Source: Zacks Investment Research More on FDA's CRL for VNDA's Tradipitant Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease. Also, per management, the FDA delayed its dec [Read more]
IMPACT SNAPSHOT EVENT TIME: ILMN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ILMN alerts
from News Quantified
ILMN
NEWS
ILMN
Earnings
ILMN
Analyst Actions
ILMN
SEC Filings
Stockreport

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis [Yahoo! Finance]

Illumina, Inc.  (ILMN) 
More Company Research Source: Yahoo! Finance
Last illumina, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: illumina.com/company/investor-information.html
VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis. Shares of the company were down 6.1% on Sept. 19 following the announcement of the news. Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach's ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years. Year to date, shares of Vanda have increased 10.2% compared with the industry's rise of 0.4%. Image Source: Zacks Investment Research More on FDA's CRL for VNDA's Tradipitant Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease. Also, per management, the FDA delayed its dec [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ILMN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS